For many women, finding the right diagnosis for recurring vaginal infections, fertility concerns, or menopausal symptoms can take months or even years. Traditional tests often provide limited information, leaving patients searching for answers. Juno Bio believes modern genomic technology can change that. The company has now secured fresh funding to expand its testing capabilities and bring precision diagnostics to more patients across the United States.
Juno Bio Raises $3.8 Million in Funding
Juno Bio, an Oakland, California-based developer of precision multi-omics and vaginal microbiome testing platforms, has raised $3.8 million in funding.
The investment was backed by Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator. The company will use the capital to expand its clinical testing infrastructure, strengthen pharmaceutical research and development partnerships, and increase the diagnostic capacity of its newly opened sequencing laboratory.
The funding supports Juno Bio’s goal of making advanced women’s health diagnostics more accessible through genomic technology.
New CLIA-Certified Laboratory to Increase Testing Capacity
A key part of the company’s expansion is its newly opened CLIA-certified sequencing laboratory in Oakland. The laboratory is dedicated to women’s health testing and allows Juno Bio to process more clinical samples while delivering detailed diagnostic reports.
The new facility also supports the company’s plans to work more closely with pharmaceutical partners on research and development projects. These collaborations are expected to help advance scientific understanding of the vaginal microbiome and support the development of future therapies.
By investing in laboratory infrastructure, Juno Bio aims to improve both the scale and quality of its diagnostic services.
Advanced Sequencing Platform Offers Comprehensive Analysis
Juno Bio was founded by Hana Janebdar, who serves as the company’s Founder and CEO.
The company has developed a next-generation sequencing and digital diagnostic platform that analyzes approximately 10,000 bacteria and fungi strains from a single patient sample. The same test also screens for four common sexually transmitted infections (STIs), giving healthcare providers a broader picture of vaginal health than many conventional testing methods.
This comprehensive approach helps clinicians better understand the vaginal microbiome and supports more informed treatment decisions.
Growing Presence in Women’s Health
Originally founded in the United Kingdom, Juno Bio has expanded its operations to the United States and continues to grow its clinical footprint.
According to the company, it has surpassed 20,000 organic test sales, reflecting increasing demand for more comprehensive diagnostic solutions. Its testing platform is designed to address conditions that are commonly linked to chronic misdiagnosis, including menopausal health concerns, fertility issues, and recurrent bacterial vaginosis.
Juno Bio’s clinical testing service is currently available across 46 U.S. states, extending access to advanced microbiome diagnostics for patients and healthcare providers.
The company also works with a medical advisory network that includes Dr. Anna Powell of Johns Hopkins, a specialist in reproductive infectious disease and vulvovaginal disorders, supporting the scientific development of its platform.
Looking Ahead
The new $3.8 million investment gives Juno Bio additional resources to expand its laboratory operations, increase testing capacity, and strengthen partnerships with pharmaceutical researchers.
As precision medicine continues to reshape healthcare, the company is focused on delivering more accurate and comprehensive diagnostics for women’s health. With its expanded infrastructure, advanced sequencing technology, and continued investment in research, Juno Bio is positioned to support healthcare providers with deeper clinical insights while helping address long-standing challenges in women’s health diagnosis.
